CanBas Co

CanBas Co Days Sales Outstanding

The Days Sales Outstanding (DSO) of CanBas Co (4575.T) as of Nov 1, 2026 is 186.00. In the previous year, Days Sales Outstanding (DSO) was 194.08 — a change of -4.17% (lower).

Days Sales Outstanding

186.00

YoY

-4.17%

Last updated:

Days Sales Outstanding (DSO) of CanBas Co is 2020 186.00 . Days Sales Outstanding (DSO) of CanBas Co was 2019 194.08 . It decreases by -4.17% lower compared to the previous year.

The CanBas Co Days Sales Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Sales Outstanding
Date
Days Sales Outstanding
Jan 1, 2015
305.12 JPY
Jan 1, 2016
194.92 JPY
Jan 1, 2017
186.25 JPY
Jan 1, 2018
186.00 JPY
Jan 1, 2019
194.08 JPY
Jan 1, 2020
186.00 JPY
The CanBas Co Days Sales Outstanding history
YEARDays Sales OutstandingYoY
186.00-4.17%
194.08+4.35%
186.00-0.13%
186.25-4.45%
194.92-36.12%
305.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co., Ltd. generates revenue through pharmaceutical research and development, focusing on basic anticancer drug discovery and early clinical development. The company develops drug discovery concepts, selects candidate compounds, conducts simple animal studies, and analyzes basic data on anticancer drug candidates entering development. It also performs preclinical studies for clinical trial applications and manages the initial phase of clinical trials. The primary buyers of these services are pharmaceutical companies seeking to advance their anticancer drug pipelines through early-stage research and development. CanBas Co., Ltd. operates with a team of 12 full-time employees, specializing in anticancer drug research. The company's services are tailored for pharmaceutical firms requiring expertise in early-stage drug development, particularly in the discovery and preclinical phases. Its focus on basic anticancer drug research and early clinical development positions it as a specialized provider in the pharmaceutical R&D sector. The firm's business model relies on providing comprehensive research services to pharmaceutical companies, including concept development, compound selection, animal studies, and data analysis. These services are critical for pharmaceutical firms to progress anticancer drug candidates from discovery to early clinical stages, ensuring efficient and effective development pathways for new treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Days Sales Outstanding (DSO) of CanBas Co is 186.00 in 2020.

Days Sales Outstanding (DSO) of CanBas Co changed from 194.08 to 186.00, representing a -4.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Sales Outstanding (DSO) CanBas Co since 2006 – with annual values, charts, and detailed analysis.

DSO measures the average number of days it takes to collect payment after a sale. Lower DSO indicates faster cash collection.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Sales Outstanding (DSO)'s CanBas Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Sales Outstanding (DSO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Sales Outstanding (DSO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CanBas Co

All Key Metrics — CanBas Co